Clinical Trial Update: Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA [Phase 2]

View source ↗

Summary

This update describes a Phase 2 clinical trial to assess the safety of ELGN-2112 in preterm infants born under 26 weeks gestational age and in IUGR infants born…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Malabsorption

Drugs mentioned

• ELGN-2112

Snippet

Sponsor: Elgan Pharma Ltd. | Conditions: Intestinal Malabsorption | Phase 2 | Status: RECRUITING